{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:47:50Z","timestamp":1791240470031,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002674","name":"Russian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-15-00344-\u041f"],"award-info":[{"award-number":["19-15-00344-\u041f"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009432","name":"Government of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmech.2022.114949","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:13:51Z","timestamp":1669306431000},"page":"114949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning"],"prefix":"10.1016","volume":"246","author":[{"given":"Liliya F.","family":"Saifina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohnad","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya M.","family":"Gubaidullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Zueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa Ali","family":"Eltayb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Ahmed","family":"El-Arabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra D.","family":"Kharlamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana A.","family":"Lenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-2433","authenticated-orcid":false,"given":"Vyacheslav E.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin A.","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114949_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","article-title":"Autoimmune mechanisms in myasthenia gravis","volume":"25","author":"Cavalcante","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejmech.2022.114949_bib2","unstructured":"J. Verschuurenellen, E. Strijbosane, A. Vincen, Neuromuscular junction disorders, in Handb. Clin. Neurol., Ed.: S.J. Pittock and A. Vincent, Vol. 133 (3rd series), Autoimmune Neurology. pp. 447-466."},{"key":"10.1016\/j.ejmech.2022.114949_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00766","article-title":"Autoregulation of acetylcholine release and micro-pharmacodynamic mechanisms at neuromuscular junction: selective acetylcholinesterase inhibitors for therapy of myasthenic syndromes","volume":"9","author":"Petrov","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114949_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.201406-1150CI","article-title":"Respiratory complications of organophosphorus nerve agent and insecticide poisoning. implications for respiratory and critical care","volume":"190","author":"Hulse","year":"2014","journal-title":"Am. J. Respir. Crit."},{"key":"10.1016\/j.ejmech.2022.114949_bib5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jat.2760","article-title":"Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon","volume":"33","author":"Petroianu","year":"2013","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114949_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jat.3662","article-title":"Reversible cholinesterase inhibitors as pretreatment for exposure to organophosphates. A review","volume":"39","author":"Lorke","year":"2019","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114949_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071521","article-title":"Combined pre- and posttreatment of paraoxon exposure","volume":"25","author":"Lorke","year":"2020","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ejmech.2022.114949_bib8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1039\/C4MD00225C","article-title":"Macrocyclic derivatives of 6-methyluracil as ligands of the peripheral anionic site of acetylcholinesterase","volume":"5","author":"Semenov","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2022.114949_bib9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/BCJ20160084","article-title":"Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment","volume":"473","author":"Kharlamova","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114949_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108236","article-title":"Slow-binding inhibitors of acetylcholinesterase of medical interest","volume":"177","author":"Lushchekina","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114949_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2017.12.034","article-title":"C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: pharmacokinetic and pharmacodynamic studies","volume":"131","author":"Petrov","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114949_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73822-6","article-title":"Slow-binding reversible inhibitor of acetylcholinesterase with long-lasting action for prophylaxis of organophosphate poisoning","volume":"10","author":"Lenina","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114949_bib13","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1021\/ja00070a007","article-title":"Molecular recognition in micelles: the roles of hydrogen bonding and hydrophobicity in adenine-thymine base-pairing in SDS micelles","volume":"115","author":"Nowick","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114949_bib14","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1002\/ejoc.200700162","article-title":"Triuracils - 1,3-Bis[\u03c9-(N-methyluracil-1-yl)alkyl]thymines and their 5,5\u2019-cyclic counterparts","author":"Semenov","year":"2007","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114949_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/jm010196t","article-title":"Pyridophens: binary pyridostigmine\u2212aprophen prodrugs with differential inhibition of acetylcholinesterase, butyrylcholinesterase, and muscarinic receptors","volume":"45","author":"Leader","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114949_bib16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","article-title":"Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis","volume":"37","author":"Punga","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejmech.2022.114949_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/S0100-879X2010005000001","article-title":"Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans","volume":"43","author":"Zimerman","year":"2010","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejmech.2022.114949_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41598-017-18307-9","article-title":"Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment","volume":"8","author":"Petrov","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114949_bib19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jat.2760","article-title":"Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon","volume":"33","author":"Petroianu","year":"2013","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114949_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jat.3662","article-title":"Reversible cholinesterase inhibitors as pretreatment for exposure to organophosphates. A review","volume":"39","author":"Lorke","year":"2019","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114949_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.ejmech.2022.114949_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114949_bib23","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor - subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2022.114949_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2105\/AJPH.38.1_Pt_1.22","article-title":"An abridged table of pobits for use in the graphic solution of the dosage-effect curve","volume":"38","author":"Weiss","year":"1948","journal-title":"Am. J. Public Health Nation's Health"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:45:39Z","timestamp":1759329939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422008510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"alternative-id":["S0223523422008510"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114949","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114949"}}